Equities Analysts Set Expectations for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Zacks Research reduced their Q1 2026 earnings per share (EPS) estimates for shares of Biogen in a research note issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $3.49 per share for the quarter, down from their prior estimate of $3.59. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen's Q2 2026 earnings at $4.30 EPS, Q3 2026 earnings at $4.07 EPS, Q4 2026 earnings at $4.09 EPS, FY2026 earnings at $15.96 EPS and FY2027 earnings at $16.84 EPS.

A number of other research analysts also recently issued reports on the company. Royal Bank of Canada reduced their price objective on Biogen from $231.00 to $225.00 and set an "outperform" rating for the company in a research note on Thursday, February 13th. Canaccord Genuity Group reduced their price objective on Biogen from $298.00 to $265.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. William Blair restated an "outperform" rating on shares of Biogen in a research note on Monday, January 13th. Jefferies Financial Group downgraded Biogen from a "buy" rating to a "hold" rating and cut their price target for the stock from $250.00 to $180.00 in a research note on Monday, December 9th. Finally, Citigroup decreased their price objective on Biogen from $160.00 to $145.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, Biogen currently has a consensus rating of "Hold" and an average target price of $213.33.

Remove Ads

Biogen Stock Performance

NASDAQ:BIIB traded down $0.45 during trading on Friday, reaching $143.09. The company's stock had a trading volume of 1,506,874 shares, compared to its average volume of 1,239,829. The firm has a market cap of $20.94 billion, a price-to-earnings ratio of 12.79, a price-to-earnings-growth ratio of 1.51 and a beta of 0.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The firm has a 50 day moving average of $142.90 and a 200-day moving average of $163.58. Biogen has a 12 month low of $128.51 and a 12 month high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Institutional Trading of Biogen

Hedge funds have recently bought and sold shares of the company. Lee Danner & Bass Inc. bought a new stake in Biogen in the 4th quarter worth approximately $25,000. Larson Financial Group LLC lifted its position in Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock worth $25,000 after buying an additional 141 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Biogen in the 3rd quarter worth approximately $33,000. Colonial Trust Co SC lifted its position in Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after buying an additional 186 shares during the last quarter. Finally, SRS Capital Advisors Inc. bought a new stake in Biogen in the fourth quarter valued at approximately $33,000. Institutional investors own 87.93% of the company's stock.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at $1,697,926.36. The trade was a 43.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.